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Abstract The acquisition of specific antibodies is para-
mount to protect children against pneumococcal diseases,
and a better understanding of how age, ethnicity and/or
Streptococcus pneumoniae (Spn) nasopharyngeal carriage
influence the acquisition of antibodies to pneumococcal
surface proteins (PSP) is important for the development of
novel serodiagnostic and immunisation strategies. IgG anti-
body titres against three conserved PSP (PhtD, PcpA and
PrtA) in the sera of 451 healthy children aged 1 to 24 months
from Israel [Jewish (50.1 %) and Bedouin (49.9 %)] were
measured by enzyme-linked immunosorbent assay (ELISA),
while nasopharyngeal swabs from these children were
assessed for the presence of Spn. Globally, anti-PhtD and
anti-PrtA geometric mean concentrations (GMC; EU/ml)
were high at <2.5 months of age [PhtD: 35.3, 95 % confi-
dence interval (CI) 30.6–40.6; PrtA: 71.2, 95 % CI 60–
84.5], was lower at 5–7 months of age (PhtD: 10, 95 % CI
8–12.4; PrtA: 17.9, 95 % CI 14.4–22.1) and only increased
after 11 months of age. In contrast, an increase in anti-PcpA
was observed at 5–7 months of age. Anti-PcpA and anti-PrtA,
but not anti-PhtD, were significantly higher in Bedouin
children (PcpA: 361.6 vs. 226.3, p00.02; PrtA: 67.2 vs.
29.5, p<0.001) in whom Spn nasopharyngeal carriage was
identified earlier (60 % vs. 38 % of carriers <6 months of
age, p00.002). Spn carriage was associated with significantly
higher anti-PSP concentrations in carriers than in non-carriers
(p<0.001 for each PSP). Thus, age, ethnicity and, essentially,
nasopharyngeal carriage exert distinct cumulative influences
on infant responses to PSP. These specific characteristics are
worthwhile to include in the evaluation of pneumococcal
seroresponses and the development of new PSP-based
vaccines.
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Introduction
Streptococcus pneumoniae (Spn) is a major cause of respi-
ratory and invasive diseases in childhood and contributes
significantly to morbidity and mortality in children [1–3]. In
industrialised countries, pneumococcal vaccination and
antibiotic treatments have markedly reduced childhood mor-
tality caused by invasive pneumococcal infections [1, 4, 5].
Pneumococcal polysaccharide-based glycoconjugate vac-
cines are immunogenic and effective, but the presence of
more than 90 different Spn serotypes [1, 6–8] and serotype
replacement [1, 2, 4, 6, 9] are limitations. New-generation
vaccines are currently under investigation, including the use
of non-polysaccharide antigens [7]. Probing the antibody
repertoire of exposed or convalescent patients for pneumo-
coccal surface proteins (PSP), Giefing et al. identified
approximately 140 protein antigens, many of them surface-
exposed [7]. The potential contribution of most of these
antigens to the serodiagnosis of pneumococcal infections
or protection against subsequent infection—including in
vaccines—remains undefined. Nonetheless, little is yet
known on the natural acquisition of antibodies to PSP
[10–12].
Three PSP were selected primarily on their availability,
their putative role(s) in bacterial pathogenesis and their
conservation across pneumococcal strains (>97 %) [13].
Pneumococcal histidine triad protein D (PhtD) belongs to
the family of surface-exposed pneumococcal proteins that
have histidine triad motifs in their amino acid sequence [14].
PhtD has been suggested to be involved in the invasion
process, and is highly conserved among various strains
[14]. Anti-PhtD antibodies have been detected in the
convalescent-phase sera of infants and children with pneu-
mococcal bacteremia, confirming that this protein is ex-
posed and recognised by the immune system during
pneumococcal disease [14, 15]. Pneumococcal choline-
binding protein A (PcpA) has been suggested to play a role
in bacterial adherence to the respiratory epithelium in the
lower respiratory tract [6]. PcpA is distinct from other
pneumococcal choline-binding proteins (PspC and CbpA)
[6, 14, 16]. Studies have shown that manganese concentra-
tion directly affects the presence of PcpA on the Spn
surface, which may explain why its expression is possibly
increased in bacteria infecting low-manganese sites, such as
the lungs and blood [6]. Serine proteinase precursor A
(PrtA) is a cell-wall-associated serine proteinase that con-
tributes to pneumococcal virulence [17]. It is also regulated
by manganese and zinc and, for this reason, we were inter-
ested in assessing whether it elicited a similar or distinct
seroresponse pattern to PcpA.
The aim of this study was, thus, to evaluate the antibody
levels produced following the natural acquisition of three
immunogenic and highly conserved PSP (PhtD, PcpA and
PrtA) in infants and young children, and to evaluate the
influence of age, ethnicity, social status, and pneumococcal
carriage on these anti-PSP responses.
Materials and methods
Patients
Healthy children less than 24 months of age were enrolled
prospectively after written informed consent at Soroka Uni-
versity Medical Center or at maternal and children health
centres in southern Israel between October 1996 and No-
vember 2006. All enrolled children came to the medical
centre for reasons other than infectious diseases or fever.
None of the children had been immunised against Spn and
none had a clinically relevant history of pneumococcal
infection. Each patient had venous blood sampling and
nasopharyngeal (NP) swab culture. Carriage was defined
as being culture-positive for Spn on an NP swab without
clinical symptoms at the time of sampling. Serum samples
were stored at −70 °C until analysis.
This study was approved by the Soroka Medical Center
and the Israel Ministry of Health Ethics Committees.
Setting
In the Negev region of southern Israel, the Jewish and
Bedouin populations live side by side. The Jewish popula-
tion is mainly urban, whereas the Bedouin population is
gradually moving away from its nomadic lifestyle [18].
Children of the two populations do not frequent the same
day-care facilities or schools, and have distinct social lives.
In 2004, the crude birth rate was 55.3 versus 21 births per
1,000 persons in the Bedouin and Jewish populations, re-
spectively [19], and the mean ± standard deviation (SD)
family size among the Bedouin population was 8.2±0.9
persons compared with 3.2±0.1 among the Jewish popula-
tion [20]. The average monthly family income was 2-fold
higher among the Jewish population [19]. Hospitalisation
rates for respiratory and other infectious diseases were
higher among Bedouins [21].
During the study period, the 7-valent pneumococcal con-
jugate vaccine (PCV7) had not yet been introduced in Israel,
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and <3 % of the population had participated in clinical trials
with one of the experimental pneumococcal conjugate
vaccines.
Pneumococcal surface proteins
PhtD, a truncated version of PcpA and a truncated histidine-
tagged version of PrtA were recombinantly expressed and
purified from Escherichia coli.
Antibody titres were measured by indirect enzyme-linked
immunosorbent assay (ELISA), as previously described
[13]. Purified PSP were coated on Immulon (Thermo Lab-
systems) plates. To allow precise quantification, eight serial
dilutions (2-fold) of serum samples were added, followed by
conjugated anti-IgG antibodies (Cappel) and ABTS sub-
strate. A common reference human antibody serum was
used in each assay and its antibody concentration in ELISA
units was defined by the reciprocal of its dilution at OD0
1.0. Assay results were expressed in EU/ml by interpolation
to the reference serum, allowing precise quantification. A
cut-off of 5 EU/ml was experimentally identified as allow-
ing the reliable detection of serum concentrations. Anti-PSP
concentrations below 5 EU/ml were given a titre of 2.5 EU/
ml. The results are expressed as geometric mean antibody
concentrations (GMC). The specificity of PhtD and PcpA
antigen-specific ELISA was demonstrated by complete loss
of binding of human antibody sera by competitive inhibition
with specific antigens, and not with other PSP as the control
antigen.
Statistical analyses were carried out using SPSS
(PASW Statistics 18.0.0; IBM Corporation, Somers, NY).
Standard descriptive statistics were used to describe socio-
demographic characteristics. Categorical data were com-
pared using Chi-square tests or Fisher’s exact tests, when
appropriate. Serologies among groups were compared by
using Student’s t-test, linear regression or the Mann–Whitney
U-test, according to the type of independent variable. Uni-
variate statistical analyses were performed for each variable
to determine its relationship to the dependent variable, being
a case patient or not. A multivariate linear regression anal-
ysis model was used to assess the goodness of fit, calculate
adjusted odds ratio (OR) and 95 % confidence interval (CI)
for variables that had p-values<0.25 in the univariate anal-
yses. For all statistical tests, differences were considered to
be significant at p<0.05 or when the 95 % CI did not
include 1.0.
Results
Four hundred and fifty-one serum samples from children
aged 1 to 24 months were included in this study. The
children were divided into five age groups, each including
at least 75 children (Table 1), with a similar distribution
among the two ethnic groups. Boys, which were slightly
more numerous overall (53.7 %), were similarly represented
in the two ethnic groups.
Pneumococcal carriage
Spn carriage was identified in 58.8 % of children overall,
equally distributed among genders (Table 1). There was a
wide distribution among Spn serotypes (>40 identified),
without a significantly predominant serotype (not shown).
No association between PSP antibody levels and pneumo-
coccal serotype was observed. The proportion of Spn
carriers increased with age, and carriage was present earlier
(p00.005) and more frequently (p<0.001) in Bedouin
children (Table 1).
Anti-PSP antibodies
Antibodies to all three PSP were detectable in each age
group. Anti-PhtD and anti-PrtA GMC were 2–3-fold higher
in 1–2.5-month-old infants than in 2.5–4- or 5–7-month-old
infants, in whom the nadir was observed (Table 2), and they
were only significantly higher in the second year of life. In
contrast, anti-PcpA GMC remained similar throughout
infancy, reflecting their earlier increase (5–7 months) to
markedly higher levels (Table 2).
Comparing anti-PSP concentrations in Bedouin and
Jewish children indicated similar anti-PhtD antibodies in
both ethnic groups (Table 2). In contrast, anti-PcpA (p<
0.05) and anti-PrtA (p<0.001) antibodies were significantly
higher in Bedouin infants. This difference was similar for
anti-PrtA in the second year of life, as these antibodies were
higher later in Jewish children. Spn acquisition is known to
trigger antibody responses; we assessed the influence of Spn
carriage at the time of sampling on anti-PSP concentrations.
Overall, anti-PSP antibodies were significantly higher in
Spn-positive children (p<0.001 for each PSP; Table 2 and
Fig. 1). This influence was statistically significant (p00.002)
in 11–15-month-old children for anti-PhtD antibodies. For
anti-PcpA antibodies, significant differences were already
present in 2.5–4-month- (p00.043) and 5–7-month-old
(p00.002) carrier infants, in whom anti-PrtA antibodies were
also higher (PrtA, p00.025) (Table 2 and Fig. 1). After the age
of 17 months, the influence of Spn carriage at sampling was
not statistically significant.
Multivariate analyses including age, ethnicity and Spn
carriage indicated significantly higher anti-PSP GMC in
carrier than non-carrier Jewish children (PhtD: 42.6 vs.
17.9; PcpA: 542.8 vs. 105.9; PrtA: 43.1 vs. 21.2; p≤0.001
for all). Interestingly, however, similarly high GMC were
observed in carrier and non-carrier Bedouin children (PhtD:
30.7 vs. 29.8; PcpA: 398.8 vs. 284; PrtA: 67.2 vs. 66.9).
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Table 1 Characteristics of the 451 healthy children enrolled in the study
Age group Total, n (median, IQR) Bedouin children, n (%) Jewish children, n (%) p-value
Age group distribution in months All 451 (6, 10) 225 (49.9) 226 (50.1) NS
<2.5b 91 (2, 1) 48 (21.3) 43 (19) NS
2.5–4b 75 (4, 1) 38 (16.9) 37 (16.4) NS
5–7b 97 (6, 1) 49 (21.8) 48 (21.2) NS
11–15b 90 (11, 1) 40 (17.8) 50 (22.2) NS
17–24b 98 (18, 0.3) 50 (22.2) 48 (21.2) NS
Male gender, n (%) 242 (53.7) 128 (56.9) 114 (50.4) NS
Streptococcus pneumoniae All 265 (58.8) 160 (60.4) 105 (39.6) <0.001
Carrier by age groupa, n (%) <2.5c 35 (38.5) 25 (52.1) 10 (23.3) 0.005
2.5–4c 42 (56) 26 (68.4) 16 (43.2) 0.028
5–7c 61 (62.9) 37 (75.5) 24 (50) 0.009
11–15c 56 (62.2) 33 (82.5) 23 (46) <0.001
17–24c 71 (72.4) 39 (78) 32 (66.7) NS
IQR interquartile range; NS not significant
a Carriage at time of sampling
b% within ethnicity
c% within age group
Table 2 Anti-PSP GMC of 451 healthy children by age group, ethnicity and carrier state
Age group (in months) n Overall (95 % CI) Bedouin children Jewish children Ethnicity Carrier Non-carrier Carrier
p-value p-value
PhtD GMC (EU/ml)
All 451 28.6 (25.3–32.2) 30.5 26.8 NS 35 21.4 <0.001
<2.5 91 35.3 (30.6–40.6) 36.6 33.8 NS 32.4 37.2 NS
2.5–4 75 17.3 (14.4–20.7) 16.1 18.7 NS 19.6 14.8 NS
5–7 97 10 (8–12.4) 10.1 9.8 NS 11.1 8.3 NS
11–15 90 34.7 (26.1–46.1) 46.7 27.3 NS 50.7 18.6 0.002
17–24 98 81.6 (63.2–105.5) 86.9 76.5 NS 102.7 44.7 NS
PcpA GMC (EU/ml)
All 451 285.9 (247.5–330.2) 361.6 226.3 0.02 450.6 149.5 <0.001
<2.5 91 166.7 (143.8–193.1) 194.3 140.4 0.036 179.5 159.1 NS
2.5–4 75 146.3 (115.5–185.1) 183.4 116 0.044 177.4 114.4 0.043
5–7 97 202.8 (144.3–285.1) 255 160.6 NS 345.8 82.1 0.002
11–15 90 386.7 (266.4–561.2) 591 275.4 NS 689.7 149.1 0.013
17–24 98 838.7 (627.7–1,120.8) 1,045.3 666.8 NS 1,104.9 406.3 NS
PrtA GMC (EU/ml)
All 451 44.5 (39.2–50.4) 67.2 29.5 <0.001 56.4 31.7 <0.001
<2.5 91 71.2 (60–84.5) 94.7 51.8 0.001 71 71.4 NS
2.5–4 75 33 (27.2–40.1) 43.2 25.1 0.006 35.4 30.3 NS
5–7 97 17.9 (14.4–22.1) 26.1 12.1 <0.001 21.8 12.7 0.025
11–15 90 38.6 (28–53.2) 80 21.5 <0.001 68.5 15.0 <0.001
17–24 98 101.2 (74.7–137.1) 148.4 67.9 0.025 128.4 54.1 NS
PSP pneumococcal surface proteins; GMC geometric mean antibody concentrations; PcpA pneumococcal choline-binding protein A; PhtD
pneumococcal histidine triad protein D, PrtA serine proteinase precursor A; NS not significant
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Discussion
This study shows that natural exposure to Spn generates
antibody responses to three highly conserved PSP in infants,
and the pattern and magnitude of these antibody responses
differ for each of the three PSP assessed.
In very young infants, anti-PSP IgG antibodies represent
passively transmitted maternal antibodies [14]. These ma-
ternal antibodies decrease over time, and active antibody
production increases with immune maturation in response to
antigenic exposure. This results in a characteristic U-type
pattern, which was previously identified for several PSP
antibodies in healthy or sick children [12, 14, 22–26]. In
our study, anti-PhtD and anti-PrtA antibodies, indeed, fol-
low this U-curve. The pattern of anti-PcpA antibodies was
different: relatively low concentrations were present in the
youngest age group as compared to toddlers, which could
result from low anti-PcpA IgG concentrations in mothers.
The high manganese (Mn++) environment in the NP does
not trigger PcpA expression by Spn [6, 27], such that
maternal NP carriage may not efficiently elicit PcpA anti-
bodies. This may explain why anti-PcpA maternal antibod-
ies were not transferred passively to young infants and were,
therefore, not detected in these young infants. However,
conversely, PrtA, which was primarily selected because its
expression is also down-regulated by Mn++, generated suf-
ficient anti-PrtA maternal antibodies to result in a charac-
teristic U-curve in infants. This suggests the existence of
additional levels of complexity, such as distinct placental
transfer, which are possibly distinct for specific antibodies.
Another difference between anti-PcpA and anti-PhtD/an-
ti-PrtA antibodies was that anti-PcpA antibodies peaked
faster and reached much higher antibody concentrations.
Anti-PcpA and anti-PrtA GMC were higher in Bedouin than
in Jewish children in all age groups, probably as a result of
their earlier Spn exposure. The number of children in a
family, lower economic income and different access to a
“hygienic environment” in each ethnic group could also
have an influence on exposure to Spn and, therefore, on
antibody responses.
Spn carrier state has been reported as a determinant factor
for the antibody levels to several PSP [12, 14, 22–24, 26].
Obaro et al. showed lower anti-PSP titres in colonised
compared to not colonised infants, raising the question that
some anti-PSP antibodies may protect against Spn carriage
[28]. In a recent study with other PSP, only certain PSP were
immunogenic in colonised subjects [29]. In our study, car-
riage at sampling was usually associated with higher anti-
body titres. This data suggest that antibodies do not reduce
nasopharyngeal carriage, because the children with the high-
est antibody levels had the highest carriage state. However,
significant GMC differences between carrier and non-carrier
children were only found in one ethnic group (Jewish chil-
dren) or in certain age groups. One could hypothesise that
population-associated genetic polymorphisms may have an
impact on the capacity to respond to Spn exposure or that
maternal antibodies exert an inhibitory effect on infant
responses. A simpler explanation would be that the obser-
vation of higher anti-PSP titres in Jewish—but not in
Bedouin—carriers than non-carriers resulted from differen-
ces in cumulative past Spn exposure: with age, a progressive
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Fig. 1 Anti-PSP GMC in 451 healthy children by Streptococcus
pneumoniae carrier state and age group. *p-value <0.05 (adjusted for
ethnicity). **p-value <0.001 (adjusted for ethnicity). PSP pneumococ-
cal surface proteins; GMC geometric mean antibody concentrations,
PcpA pneumococcal choline-binding protein A, PhtD pneumococcal
histidine triad protein D, PrtA serine proteinase precursor A
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responses is, indeed, expected. However, the frequency of
past exposure to Spn is virtually impossible to assess in
children and one can only hypothesise about different expo-
sures in different ethnic groups due to several factors, which
include the number of persons in a household.
Our study has several limitations. Pairs of maternal–
infant sera were not available and children were sampled
only once. The study design was cross-sectional; a longitu-
dinal cohort study would have provided information on the
individual impact of age and/or carriage. However, this
limitation is compensated, at least in part, by the inclusion
of a larger number of children in each age group than the
number of subjects which could be followed longitudinally
without major resources. Another limitation is that Spn
carriage was only assessed at the time of blood sampling.
Reassuringly, however, carriage rates were similar to those
reported in other studies [30, 31]. In this population with
highly prevalent Spn, it is highly likely that most, if not all,
children carried Spn at least once before being tested for
anti-PSP, even in the absence of a positive culture at the time
of sampling. Our study design did not allow us to distin-
guish the impact of individual social or economic status on
antibody response. We, therefore, used only ethnicity to
differentiate the two groups, which, according to the Central
Bureau of Statistics of Israel, indeed, have very different
lifestyles and status. It is, therefore, possible that some
“atypical” families did not belong to the “typical” environ-
ment of their ethnic community.
PhtD, PcpA and PrtA elicit significant anti-PSP
responses in (very) young children, with significantly dis-
tinct patterns. Young age delays responses to PhtD and PrtA
for many months, possibly because of inhibition due to
higher maternal antibodies; in contrast, anti-PcpA responses
are elicited earlier in life. PcpA responses are significantly
higher in pneumococcal carriers than non-carriers. Differ-
ences in social patterns result in distinct patterns of anti-PSP
responses. Defining the influence of age and prior pneumo-
coccal exposure on specific anti-PSP responses in healthy
children of a given community is, thus, necessary for the
development of new pneumococcal vaccines based on PSP.
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